Company intelligence / Profile preview

Respiri

Melbourne, Victoria, Australiarespiri.co ↗

Ownership: Private
Development stage: Other

Overview

The company’s flagship product, the wheezo® device—an FDA-approved Class II medical device—enables objective remote detection of wheezing. It integrates with digital platforms to support remote patient monitoring programs targeting asthma and COPD. Clinical results highlight improved patient engagement and reduced hospital admissions through evidence-based care management programs.[1][5] The solution has begun use in the US market with positive early adoption.[7] No drug clinical trials are conducted as it’s a non-pharmacological/digital solution.

Therapeutic areas: Pulmonology
Modalities: Device (wheezo® medical device)Software/Digital health platformNon-pharmacological therapy (remote monitoring)
Industry: Physiological Monitoring

Partnerships

ACCESS/RPM integration partners in the US healthcare system

Beyond the preview

Go deeper on Respiri.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Respiri.

Explore the full profile